Skip to main content
. 2013 Jul 29;17(5):579–591. doi: 10.1016/j.bjid.2013.03.004

Table 4.

Curcumin examined for possible effects on animal models of malaria.

Mouse Treatment schedule
Treatment effect Ref.
Dose Days p.i. Method
Albino mice (P. berghei ANKA) Curcuminoids liposomes
10 mg/kg
20 mg/kg
40 mg/kg
0–3 IV For 10–20 mg/kg group, 60–70% parasitemia on day 6, died by 7–8 days.
For 40 mg/kg group, suppressed parasitemia up to 9 days and prolonged survival up to 11 days.
112



Swiss mice (P. berghei ANKA) Curcumin 100 mg/kg for 5 days 0–2 Oral Curcumin treatment resulted in overall survival rate of 29% compared to 0% in vehicle fed animals 21 days p.i., decreased blood parasitemia by 80–90%. 96



Swiss mice (P. yoelli) Curcumin loaded chitosan nanoparticles 33.33 mg/kg 3–10 Oral Curcumin bound chitosan nanoparticles prolonged survival up to 15 days p.i. in comparison to day 9 of p.i. in control mice.
Curcumin alone lead to survival of 33% mice whereas group treated with curcumin nanoparticle showed 100% survival.
113



Albino mice (P. berghei) Curcuminoid loaded SLN, NLC 100 mg/kg IP Mice treated with drug loaded SLN and NLC showed significantly 2 fold longer survival as compared to control and free curcuminoids. All groups showed 100% mortality at the end of study. 114



ICR Harlam-Sprague Dawley and C57BL/6 mice (P. berghei ANKA MRA-311/GFP) 50 mg/kg twice a day 0–5 IP/Gavage IP injection of 25 mg/kg/d Curcumin on day 1–9 p.i. was beneficial in case of PbA GFP infection in ICR mice; no effect was seen in case of PbA/ICR infection.
Gavage treatment of PbA infected C57BL/6 prevented CM and delayed death by 10 days, did not change initial parasitemia and no significant effect was seen in ICR mice.
115